Colorectal cancer risk in relation to use of acid suppressive medications

被引:30
作者
Chubak, Jessica [1 ,2 ]
Boudreau, Denise M. [1 ,3 ]
Rulyak, Stephen J. [4 ]
Mandelson, Margaret T. [1 ,2 ,5 ]
机构
[1] Grp Hlth Ctr Hlth Studies, Seattle, WA 98101 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[4] Univ Washington, Dept Med, Seattle, WA USA
[5] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA
关键词
colorectal cancer; acid suppressive medications; proton pump inhibitors; histamine receptor antagonists; PUMP INHIBITOR USE; SERUM GASTRIN; COLON-CANCER; CYCLOOXYGENASE-2; INHIBITORS; EPITHELIAL-CELLS; TRANSGENIC MICE; INVITRO GROWTH; HYPERGASTRINEMIA; RAT; PROLIFERATION;
D O I
10.1002/pds.1749
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Acid suppressants are commonly prescribed medications. Laboratory studies suggest a mechanism by which they could increase colorectal cancer (CRC) risk. A few epidemiologic studies have investigated acid suppressant use and CRC risk; none has documented an overall association. We sought to investigate whether acid suppressants are associated with CRC risk. Methods We conducted a case-control study among members of an integrated healthcare delivery system in Washington State. Cases (N = 641) were diagnosed with CRC between 2000 and 2003; controls (N = 641) were randomly selected from enrollees and matched to cases on age, sex, and length of enrollment. We used conditional logistic regression to estimate the odds ratios (ORS) and 95% confidence intervals (CI) for CRC associated with the use of any acid suppressive medication, proton pump inhibitors (PPIs) only, histamine receptor antagonists (H2 blockers) only, or both PPIs and H2 blockers in relation to the use of neither PPIs nor H2 blockers. Results Use of PPIs exclusively was modestly associated with an increased risk of CRC, however this finding was consistent with chance and based on a small number of patients exposed (OR = 1.7; 95%CI = 0.8, 4.0). H2 blocker use alone was not related to CRC risk (OR = 0.8; 95%CI = 0.6, 1.1). Conclusions PPI use may be modestly associated with CRC risk; further research should be conducted in populations with long-term PPI use. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:540 / 544
页数:5
相关论文
共 29 条
[1]   Cyclooxygenase-2 inhibitors in colorectal cancer prevention: Point [J].
Arber, Nadir .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (08) :1852-1857
[2]   Cardiovascular Medication Use and Risk for Colorectal Cancer [J].
Boudreau, Denise M. ;
Koehler, Elizabeth ;
Rulyak, Stephen J. ;
Haneuse, Sebastien ;
Harrison, Robert ;
Mandelson, Margaret T. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (11) :3076-3080
[3]   Statin use and prostate cancer risk in a large population-based setting [J].
Boudreau, Denise M. ;
Yu, Onchee ;
Buist, Diana S. M. ;
Miglioretti, Diana L. .
CANCER CAUSES & CONTROL, 2008, 19 (07) :767-774
[4]  
CHARNLEY RM, 1992, ANN ROY COLL SURG, V74, P138
[5]   GASTRIN AND THE GROWTH OF THE GASTROINTESTINAL-TRACT [J].
EKUNDAYO, AA ;
LEE, CY ;
GOODLAD, RA .
GUT, 1995, 36 (02) :203-208
[6]   Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies [J].
Flossmann, Enrico ;
Rothwell, Peter M. .
LANCET, 2007, 369 (9573) :1603-1613
[7]  
Iwao T, 1995, HEPATO-GASTROENTEROL, V42, P677
[8]   Cyclooxygenase-2 inhibitors in colorectal cancer prevention: Counterpoint [J].
Jankowski, Janusz ;
Hunt, Richard .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (08) :1858-1861
[9]   EFFECT OF LONG-TERM TREATMENT WITH OMEPRAZOLE ON SERUM GASTRIN AND SERUM GROUP-A AND GROUP-C PEPSINOGENS IN PATIENTS WITH REFLUX ESOPHAGITIS [J].
JANSEN, JBMJ ;
KLINKENBERGKNOL, EC ;
MEUWISSEN, SGM ;
DEBRUIJNE, JW ;
FESTEN, HPM ;
SNEL, P ;
LUCKERS, AEG ;
BIEMOND, I ;
LAMERS, CBHW .
GASTROENTEROLOGY, 1990, 99 (03) :621-628
[10]   HYPERGASTRINEMIA AND COLORECTAL CARCINOGENESIS IN THE RAT [J].
KARLIN, DA ;
MCBATH, M ;
JONES, RD ;
ELWYN, KE ;
ROMSDAHL, MM .
CANCER LETTERS, 1985, 29 (01) :73-78